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Background: CCN1 plays distinct roles in various tumor types, but little is known regarding the role of CCN1 in
leukemia.
Methods: We analyzed CCN1 protein expression in leukemia cell lines and in AML bone marrow samples. We also
evaluated the effects of antibody- or siRNA-mediated inhibition of CCN1 on the growth of two AML cell lines (U937
and Kasumi-1 cells) and on the MEK/ERK pathway, β-catenin and other related genes.
Results: U937 and Kasumi-1 cells had markedly higher CCN1 expression than the 5 other leukemia cell lines, and
CCN1 protein expression was higher in the AML bone marrow samples than in the normal bone marrow samples.
Blocking CCN1 with an antibody in U937 and Kasumi-1 cells suppressed proliferation, increased apoptosis,
down-regulated Bcl-xL and c-Myc expression, up-regulated Bax expression, and had no effect on Survivin.
siRNA-mediated down-regulation of CCN1 inhibited the proliferation and colony formation of U937 and
Kasumi-1 cells and increased cytarabine-induced apoptosis. Furthermore, CCN1 siRNA reduced MEK and ERK
phosphorylation without affecting β-catenin; the CCN1 antibody similarly affected MEK and ERK phosphorylation. These
changes in phosphorylation could influence the expression of Bcl-xL, c-Myc and Bax in AML cells.
Conclusions: The data suggested that CCN1 is a tumor promoter in AML that acts through the MEK/ERK pathway to
up-regulate c-Myc and Bcl-xL and to down-regulate Bax.
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CCN1 (Cyr61, cysteine-rich 61), a member of the CCN
protein family, is an extracellular matrix-associated pro-
tein [1]. Domains within the CCN1 protein have binding
sites for the various integrins or heparan sulfate proteo-
glycans (HSPGs) on different cell types, where they ac-
tivate distinct signaling pathways. CCN1 is essential for
development, inflammation, cell adhesion, migration,
tumorigenesis and cell survival [2].
CCN1 plays unique roles in different tumor types: it
is an oncogenic factor for cancers of the breast [3],
prostate [4], and stomach [5] as well as for glioma [6],
esophageal squamous cell carcinoma [7], and chondro-
sarcoma [8]. In contrast, CCN1 is a tumor suppressor in
non-small cell lung cancer [9], endometrial adenocar-
cinoma [10] and melanoma [11]. The role of CCN1 in* Correspondence: weikesi2004@hotmail.com
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unless otherwise stated.hepatocellular carcinoma is controversial [12,13]. How-
ever, the role of CCN1 in leukemia is unknown.
Numerous signaling pathways have been implicated in
acute myeloid leukemia (AML), including the Wnt/β-
catenin [14], RAF/MEK/ERK, and PI3K/AKT [15] path-
ways. Extracellular signal-regulated kinase (ERK), a
member of the MAP kinase family, can be phosphorylated
and activated by MEK (mitogen-activated protein kinase/
extracellular signal-regulated kinase kinase). Markedly
increased MEK or ERK activity has been detected in
most cases of AML [16,17], and ERK activation confers
a poor prognosis on AML patients [18]. Inhibition of
MEK or ERK suppresses AML cell growth and induces
apoptosis [19-21].
Here, we show that CCN1 is expressed in two AML
cell lines (U937 and Kasumi-1) and in AML bone marrow
samples but not in other leukemia cell lines, such as Jurkat. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cells. Antibody-mediated CCN1 inhibition increased the
apoptosis of both U937 and Kasumi-1 cells; siRNA-
mediated CCN1 down-regulation inhibited U937 and
Kasumi-1 cell growth and increased cytarabine-induced
apoptosis. We demonstrated that CCN1 influences the
MEK/ERK pathway in AML cells, potentially regulating c-
Myc, Bcl-xL and Bax. These findings suggest that CCN1
is elevated in AML and promotes survival through the
MEK/ERK pathway by up-regulating c-Myc and Bcl-xL
and by down-regulating Bax. CCN1 could be a diagnostic
marker and a therapeutic target for AML.Results
CCN1 expression in leukemia cell lines and AML bone
marrow samples
We analyzed CCN1 expression in seven leukemia cell
lines and found the highest levels in two AML lines,
U937 and Kasumi-1. CCN1 was undetectable in another
AML cell line, HL-60 (Figure 1A). We extracted protein
from the mononuclear cells in bone marrow samples
and analyzed CCN1 expression to determine whether
CCN1 was up-regulated in human AML. There was
higher CCN1 expression in the AML samples than in
the normal bone marrow samples (Figure 1B-D).Figure 1 CCN1 expression in leukemia cell lines and AML bone
marrow samples. (A) Western blotting for CCN1 protein expression
in leukemia cell lines. (B-D) Western blotting for CCN1 protein
expression in AML bone marrow samples and in normal bone
marrow samples from healthy donors (#5-8: AML-M1; #13-17: AML-M2;
#18-19: AML-M3; #20: AML-M4; #21-24: AML-M5). β-actin served as the
loading control. BM, bone marrow.Blocking CCN1 with an antibody increased apoptosis in
U937 and Kasumi-1 cells
CCN1 is a secreted protein that binds to cell-surface re-
ceptors to activate a series of signaling pathways [2,22].
We used an antibody to inhibit CCN1 and examined the
role of CCN1 in U937 and Kasumi-1 cell growth.
After a 24-hour incubation with the CCN1 antibody,
U937 and Kasumi-1 cell growth was inhibited in a dose-
dependent manner compared with a control IgG anti-
body (Santa Cruz Biotechnology) (Figure 2A, B), and
apoptosis was increased (Figure 2C-D). Inhibiting CCN1
activity with the antibody decreased c-Myc and Bcl-xL
expression, up-regulated Bax expression and had no ef-
fect on Survivin expression (Figure 2E).
Neither the CCN1 antibody nor the control IgG had
an effect on the growth or apoptosis of Jurkat cells, a
CCN1-negative cell line (Figure 2F-G).
CCN1 siRNA suppressed U937 and Kasumi-1 cell growth
and enhanced the response to cytarabine
We knocked down CCN1 expression with siRNA and
constructed stable cell lines (U937/siCCN1 and Kasumi-
1/siCCN1) to further study the role of CCN1 in AML
cells.
CCN1 siRNA suppressed the proliferation and colony
formation of both AML cell lines (Figure 3A-C) to a
similar extent as the CCN1-blocking antibody. However,
CCN1 siRNA did not increase the percentage of apop-
totic cells (data not shown). CCN1 siRNA suppressed
c-Myc and Bcl-xL expression and up-regulated the
proapoptotic gene Bax (Figure 3D) but had no effect on
Survivin expression. AML cells were treated with cyta-
rabine, a common AML therapeutic [23], to determine
whether this would render them more susceptible to
apoptosis. Cytarabine increased the apoptosis of U937 and
Kasumi-1 cells treated with CCN1 siRNA compared with
the control cells (Figure 3E).
The MEK/ERK pathway, but not β-catenin, was involved in
CCN1 function in AML cells
CCN1 regulates β-catenin in esophageal squamous car-
cinoma and lung cancer cells [24,25]. We previously
showed that CCN1 is a direct target of β-catenin signal-
ing in hepatocellular carcinoma (HCC), where it may be
important for cancer progression [13]. We therefore de-
termined whether CCN1 functioned in association with
β-catenin in AML. However, we found that CCN1 did
not affect β-catenin expression or phosphorylation in
whole-cell or nuclear extracts (Figure 4A).
Previous studies have shown that CCN1 activates ERK
in ovarian carcinoma cells [26] and osteoblasts [27].
Here, we demonstrated that inhibiting CCN1 reduced
ERK phosphorylation but not ERK expression (Figure 4A).
We next examined the expression of MEK, the major
Figure 2 The CCN1-blocking antibody suppressed U937 and Kasumi-1 cell survival. U937 and Kasumi-1 cells were treated with the CCN1
antibody or the control antibody (IgG) for 24 hours. (A, B) Cell proliferation was measured using a CCK-8 reagent. (C-D) The percentage of apoptotic
cells was determined using Annexin V-APC/PI staining. (E) Western blotting in cells treated with antibodies (0.5 μg/ml) for 24 hours. β-actin served as
the loading control. (F-G) Jurkat cells were treated with the CCN1 antibody, and proliferation and apoptosis were measured. **p < 0.01.
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MEK phosphorylation but not its overall expression. The
effects of CCN1 on MEK/ERK were also confirmed using
the CCN1-neutralizing antibody (Figure 4B). We treated
cells with the MEK/ERK inhibitor PD98059 to determine
whether MEK and ERK were associated with the CCN1-
mediated regulation of Bcl-xL, c-Myc and Bax. Our re-
sults indicated that PD98059 had similar effects on these
proteins (Figure 4C).
Discussion
Our results showed that CCN1 was overexpressed in two
AML cell lines (U937 and Kasumi-1) and in AML bone
marrow samples. However, CCN1 was undetectable incertain AML samples and in one AML cell line (HL-60
cells). These data suggested that CCN1 is not the only
factor necessary for AML cell survival. CCN1 may be a
tumor promoting factor in AML and could potentially
be a diagnostic marker for AML. Our data also showed
that CCN1 acts through the MEK/ERK pathway, not
the β-catenin/Survivin pathway (Figure 4D).
CCN1 has distinct effects on apoptosis in different
cells. CCN1 enhances the Fas-mediated apoptosis of skin
fibroblasts [28] and the TRAIL-induced apoptosis of
prostate carcinoma cells [29] and induces apoptosis in fi-
broblasts [30]. In contrast, CCN1 inhibits apoptosis in-
duced by anti-cancer drugs in breast cancer cells [31,32]
and in ovarian carcinoma cells [26,33,34]. Our results
Figure 3 The influence of CCN1 siRNA on U937 and Kasumi-1 cells. (A, B) CCK-8 reagent was used to measure AML cell proliferation. h, hour.
(C) Cells were plated in 6-well plates (2000 cells/well), and the colonies were counted after 7 days. (D) Western blotting in AML cells treated with
CCN1 siRNA. β-actin served as the loading control. (E) The cells were treated with cytarabine (2 μmol/L) for 18 hours, stained with Annexin V-APC/PI
and analyzed by flow cytometry. **p < 0.01.
Figure 4 The MEK/ERK pathway was involved in CCN1 activity in AML. (A) Western blotting to determine the influence of CCN1 siRNA on
β-catenin, MEK and ERK. Histone H1 served as the loading control for nuclear protein. (B) Western blotting to illustrate the influence of a 3-hour
incubation with the CCN1 antibody on MEK and ERK. (C) Western blotting to determine the influence of a MEK/ERK inhibitor (PD98059, 20 μmol/L) on
c-Myc, Bcl-xL and Bax. β-actin served as the loading control. (D) Schematic of the proteins related to CCN1 in AML cells. p-: phospho-.
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apoptosis of two AML cell lines, suggesting that CCN1
inhibits the apoptosis of AML cells. Moreover, CCN1
siRNA inhibited the proliferation and colony formation
of AML cells without a concomitant increase in apop-
tosis. AML cell growth was more robustly inhibited by
the CCN1 antibody than by the CCN1 siRNA. Nonethe-
less, CCN1 siRNA rendered AML cells more sensitive to
cytarabine-induced apoptosis.
Previous studies have shown that c-Myc is overex-
pressed [35] and functions as a proto-oncogene in AML
[36,37]; here, we show that inhibiting CCN1 down-
regulated c-Myc protein expression. In AML, Bcl-xL
acts as an anti-apoptotic factor, Bax acts as a pro-
apoptotic factor [38], and Survivin is regarded as an
anti-apoptotic factor [39]. Our finding that inhibiting
CCN1 down-regulated Bcl-xL and up-regulated Bax
expression without affecting Survivin suggested that
CCN1 regulates the proliferation and apoptosis of
AML cells through c-Myc, Bcl-xL and Bax.
β-catenin, which is overexpressed in AML, is required
for the self-renewal of AML stem cells [40-43], and inhi-
biting β-catenin suppresses the proliferation of AML
cells [43,44]. β-catenin is regulated by CCN1 in esopha-
geal squamous carcinoma and lung cancer [24,25]. We
investigated whether CCN1 function in AML is related
to β-catenin, but our finding that CCN1 inhibition had
no effect on β-catenin or its target gene Survivin [45]
does not support this relationship.
As mentioned in the introduction, ERK is activated in
AML and is a potential target for AML therapy. ERK is
regulated by CCN1 in breast cancer and during osteo-
blast differentiation [27,32]. We found that MEK/ERK
was regulated by CCN1 in AML cells, and MEK/ERK
had the same effect as CCN1 on the regulation of Bcl-xL,
c-Myc and Bax. Our study suggests that CCN1 regulates
Bcl-xL, c-Myc, and Bax and acts as a tumor promoter
through the MEK/ERK pathway. MEK/ERK inhibition
enhances the response of AML cells to several chemi-
cal treatments [46-50], including cytarabine [51]; there-
fore, we hypothesize that inhibiting CCN1 increases
the cytarabine-induced apoptosis of AML cells by down-
regulating the MEK/ERK signaling pathway.
Conclusions
We demonstrated that CCN1 is up-regulated in AML
bone marrow samples and that CCN1 promotes AML
cell growth. These functions of CCN1 involve the activa-
tion of the MEK/ERK pathway, but not the β-catenin/
Survivin pathway, with the consequent up-regulation of
c-Myc and Bcl-xL and down-regulation of Bax. Our
study furthers our understanding of the role of CCN1 in
AML and provides a potential alternative therapeutic
target and/or diagnostic marker for AML.Methods
Cell lines, primary samples and reagents
The U937 and Kasumi-1 AML cell lines, the Jurkat and
CEM T-ALL cell lines, and the K562 CML cell line were
maintained in RPMI-1640 medium (Hyclone) with 10%
fetal bovine serum (FBS, Gibco). The KU812 CML cell
line and the HL-60 AML cell line were maintained in
IMDM medium (Hyclone) with 20% FBS, and HEK293
cells were maintained in DMEM (Hyclone) with 10% FBS.
Bone marrow samples from sixteen newly diagnosed
and untreated AML patients and from 8 healthy donors
were obtained from Chongqing Xinqiao Hospital. The
patients and healthy donors provided informed consent,
and the study was approved by the Ethical Committee of
Third Military Medical University. Mononuclear cells
were isolated by density gradient centrifugation using
Ficoll-Hypaque (Tianjin TBD, China).
The ERK inhibitor PD98059 (Sigma-Aldrich) was dis-
solved in DMSO (Sigma-Aldrich). Cytarabine was pur-
chased from Sigma-Aldrich.
RNA interference
The CCN1 siRNA targeted the sequence 5′-GGGAA
AGTTTCCAGCCCAA-3′, and the control sequence did
not target any genes. The sequences were cloned into
the pSEB-hus plasmid, and this plasmid was transfected
into HEK293 cells along with the pCL-Ampho plasmid
to package retrovirus. Retroviral supernatants were used
to infect U937 and Kasumi-1 cells. The infected cells
were maintained under selection using Blasticidin S
(Invitrogen, USA). The cells infected with CCN1 siRNA
were termed U937/siCCN1 or Kasumi-1/siCCN1; the
control cells were denoted U937/siControl or Kasumi-1/
siControl.
Apoptosis and proliferation assays
Apoptosis assay: Cells were washed 3 times with ice-
cold PBS and stained with Annexin V-APC (Keygentec,
China) and propidium iodide (PI, Sigma-Aldrich). Apop-
totic cells were identified by flow cytometry (BD Bio-
sciences) based on positive staining for Annexin V-APC
and PI negativity.
Proliferation assay: Ten microliters of CCK-8 reagent
(Dojindo, Japan) was added to the wells of 96-well plates
in which cells were cultured (100 μl/well). After a 90-
minute incubation at 37°C, the OD values were mea-
sured using a Bio-Rad Microplate Reader.
Colony formation assay
Cells (2 × 103) were plated in 6-well plates in a methyl-
cellulose (Sigma-Aldrich) semi-solid medium (final con-
centration, 1%). After seven days, colonies containing
more than 40 cells were counted.
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Western blotting was performed as described previously
[13]. The following antibodies were used: CCN1 anti-
body (Abcam), β-actin antibody (Santa Cruz Biotech-
nology), Bcl-xL antibody (Cell Signaling Technology),
c-Myc antibody (Cell Signaling Technology), Bax antibody
(Santa Cruz Biotechnology), MEK antibody (Cell Signaling
Technology), phospho-MEK antibody (Ser217/221, Cell
Signaling Technology), ERK antibody (Cell Signaling
Technology), phospho-ERK antibody (Thr202/Tyr204,
Cell Signaling Technology), β-catenin antibody (Cell Sig-
naling Technology), phospho-β-catenin antibody (Ser33/
Ser37/Thr41, Cell Signaling Technology), and Survivin
antibody (Cell Signaling Technology).
Gel electrophoresis and transfer as well as the chemilu-
minescence detection were conducted using the Bio-Rad
Laboratories system.
Nuclear protein was extracted using a nuclear protein
extraction kit (Beyotime, China), and an anti-Histone H1
antibody (Santa Cruz Biotechnology) was used as the
loading control.
Statistical analysis
The experiments were conducted three times, and the
data are presented as the means ± SD. Significance was
determined by Student’s t-test using SPSS software.
p < 0.05 was considered to be statistically significant.
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